David Qualls

582 total citations
23 papers, 334 citations indexed

About

David Qualls is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, David Qualls has authored 23 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pathology and Forensic Medicine and 6 papers in Molecular Biology. Recurrent topics in David Qualls's work include CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (9 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). David Qualls is often cited by papers focused on CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (9 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). David Qualls collaborates with scholars based in United States, Netherlands and Canada. David Qualls's co-authors include Gilles Salles, Jeremy S. Abramson, Shuli Li, Yi‐Bin Chen, Ephraim P. Hochberg, Zachariah DeFilipp, Fabian M. Troschel, Shahein Tajmir, Andrew Staron and Areej El‐Jawahri and has published in prestigious journals such as Blood, PLoS ONE and Cancer Cell.

In The Last Decade

David Qualls

23 papers receiving 324 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Qualls United States 13 140 109 74 65 54 23 334
Bülent Ündar Türkiye 12 109 0.8× 49 0.4× 21 0.3× 101 1.6× 50 0.9× 51 407
Kouichi Isobe Japan 13 127 0.9× 163 1.5× 116 1.6× 65 1.0× 31 0.6× 30 430
Jan Rekowski Germany 9 59 0.4× 90 0.8× 36 0.5× 31 0.5× 18 0.3× 29 355
Yeu‐Chin Chen Taiwan 11 51 0.4× 38 0.3× 32 0.4× 46 0.7× 54 1.0× 55 313
Anita Tahlan India 10 62 0.4× 37 0.3× 56 0.8× 25 0.4× 19 0.4× 45 382
A K Karak India 11 37 0.3× 49 0.4× 43 0.6× 50 0.8× 86 1.6× 43 442
Carmen González‐Vela Spain 12 38 0.3× 84 0.8× 16 0.2× 56 0.9× 37 0.7× 37 383
M. Le Besnerais France 11 20 0.1× 32 0.3× 28 0.4× 35 0.5× 42 0.8× 23 290
Yen‐Kung Chen Taiwan 12 103 0.7× 42 0.4× 80 1.1× 14 0.2× 27 0.5× 34 494

Countries citing papers authored by David Qualls

Since Specialization
Citations

This map shows the geographic impact of David Qualls's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Qualls with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Qualls more than expected).

Fields of papers citing papers by David Qualls

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Qualls. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Qualls. The network helps show where David Qualls may publish in the future.

Co-authorship network of co-authors of David Qualls

This figure shows the co-authorship network connecting the top 25 collaborators of David Qualls. A scholar is included among the top collaborators of David Qualls based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Qualls. David Qualls is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qualls, David, Dana C. Matthews, Robert Redd, et al.. (2024). A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. Blood Advances. 9(3). 455–462. 8 indexed citations
2.
Qualls, David, Philippe Armand, & Gilles Salles. (2024). The current landscape of frontline large B-cell lymphoma trials. Blood. 145(2). 176–189. 7 indexed citations
3.
Qualls, David & Caron A. Jacobson. (2023). Comorbidities in DLBCL: too "Severe4" CAR-T therapy?. Blood Advances. 7(14). 3469–3471. 1 indexed citations
4.
Qualls, David, Ariela Noy, David J. Straus, et al.. (2023). Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma. 64(3). 738–741. 8 indexed citations
5.
Kim, Justin, David Qualls, Madeline A. Hwee, et al.. (2022). Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses. Cancer Cell. 40(7). 738–753.e5. 32 indexed citations
6.
Qualls, David & Gilles Salles. (2022). Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica. 107(1). 19–34. 21 indexed citations
7.
Qualls, David, Michael J. Buege, Phuong Dao, et al.. (2022). Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study. Blood. 140(Supplement 1). 787–789. 16 indexed citations
8.
Qualls, David, Anita Kumar, & Zachary D. Epstein‐Peterson. (2022). Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies. Leukemia & lymphoma. 63(11). 2515–2527. 2 indexed citations
9.
Qualls, David, Karissa Whiting, Anita Kumar, et al.. (2022). A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma. Blood Advances. 6(18). 5262–5266. 3 indexed citations
10.
Palomba, M. Lia, David Qualls, Sébastien Monette, et al.. (2022). CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. Journal for ImmunoTherapy of Cancer. 10(2). e004128–e004128. 26 indexed citations
11.
Qualls, David & Gilles Salles. (2021). Optimizing CAR T cell therapy in lymphoma. Hematological Oncology. 39(S1). 104–112. 12 indexed citations
12.
Kunitoki, Keiko, M. Lisa Zhang, Marina Kem, et al.. (2021). Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance. Modern Pathology. 35(5). 615–624. 13 indexed citations
13.
Qualls, David, Gregory D. Lewis, Vaishali Sanchorawala, & Andrew Staron. (2019). Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature. American Journal of Transplantation. 19(11). 3185–3190. 17 indexed citations
14.
Qualls, David, Harish Seethapathy, Shahein Tajmir, et al.. (2019). Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis. Journal for ImmunoTherapy of Cancer. 7(1). 356–356. 35 indexed citations
15.
DeFilipp, Zachariah, Fabian M. Troschel, David Qualls, et al.. (2018). Evolution of Body Composition Following Autologous and Allogeneic Hematopoietic Cell Transplantation: Incidence of Sarcopenia and Association with Clinical Outcomes. Biology of Blood and Marrow Transplantation. 24(8). 1741–1747. 37 indexed citations
16.
Qualls, David & Jeremy S. Abramson. (2018). Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma. Haematologica. 104(1). 25–34. 32 indexed citations
17.
Qualls, David, Shuli Li, Andrew M. Brunner, et al.. (2017). High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement. Clinical Lymphoma Myeloma & Leukemia. 17(12). 884–888. 11 indexed citations
18.
Qualls, David, Jeffrey R. Leonard, Martin S. Keller, José Pineda, & Julie C. Leonard. (2015). Utility of magnetic resonance imaging in diagnosing cervical spine injury in children with severe traumatic brain injury. The Journal of Trauma: Injury, Infection, and Critical Care. 78(6). 1122–1128. 16 indexed citations
19.
Qualls, David, Keith Crosby, Hilda Brown, & David Borchelt. (2013). An Analysis of Interactions between Fluorescently-Tagged Mutant and Wild-Type SOD1 in Intracellular Inclusions. PLoS ONE. 8(12). e83981–e83981. 7 indexed citations
20.
Qualls, David, et al.. (2013). Features of wild-type human SOD1 limit interactions with misfolded aggregates of mouse G86R Sod1. Molecular Neurodegeneration. 8(1). 46–46. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bülent Ündar Breakdown of academic impact, for papers by Kouichi Isobe Breakdown of academic impact, for papers by Jan Rekowski Breakdown of academic impact, for papers by Yeu‐Chin Chen Breakdown of academic impact, for papers by Anita Tahlan Breakdown of academic impact, for papers by A K Karak Breakdown of academic impact, for papers by Carmen González‐Vela Breakdown of academic impact, for papers by M. Le Besnerais Breakdown of academic impact, for papers by Yen‐Kung Chen
Rankless by CCL
2026